Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ever Supreme Bio Technology Co., Ltd (6712.TWO)
Taichung, TW
This enterprise is dedicated to the investigation, advancement, and creation of pharmaceutical treatments leveraging human mesenchymal stem cells and immune cells. Its current portfolio features UMC01, a drug candidate undergoing Phase I clinical evaluation for addressing conditions such as myocardial infarction and stroke. Additionally, ADCV01 is progressing through Phase II clinical trials as a potential therapy for aggressive brain tumors. The company also develops CAR001, an innovative chimeric antigen receptor immune cell product, alongside bone-marrow stem cells (BMSC) used in managing chronic stroke, severe osteoarthritis, and spinal cord injuries. Established in 2016, the firm operates from its headquarters in Taichung, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.36% | +1.45% | -1.06% | -9.71% | -13.35% | -14.94% | -6.43% | -14.26% | -42.65% | +124.38% | +124.38% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+9.0% ★ Q1'26: +7.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+17.9% Q1'26: +27.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+41.9% Q1'26: +84.4% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+43.1% ★ Q1'26: +46.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+31.8% ★ Q1'26: +27.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+9.0% Q1'26: +17.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.09× ★ Q1'26: 0.11× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
438.84M
est: 439.00M (0.0%)
|
627.51M
est: 628.00M (-0.1%)
|
758.39M
est: 736.00M (+3.0%)
|
933.81M
est: 940.00M (-0.7%)
|
1.02B
est: 1.02B (-0.4%)
|
1.20B
1.20B – 1.20B
+17.0% YoY
|
| EBITDA |
433.26M
est: 163.01M (+165.8%)
|
300.16M
est: 233.19M (+28.7%)
|
655.52M
est: 273.29M (+139.9%)
|
491.76M
est: 618.15M (-20.4%)
|
439.00M
est: 672.08M (-34.7%)
|
786.50M
786.50M – 786.50M
+17.0% YoY
|
| EBIT |
397.44M
est: 144.22M (+175.6%)
|
264.61M
est: 206.32M (+28.3%)
|
623.22M
est: 241.80M (+157.7%)
|
460.87M
est: 577.93M (-20.3%)
|
439.00M
est: 628.34M (-30.1%)
|
735.32M
735.32M – 735.32M
+17.0% YoY
|
| Net Income |
369.60M
est: 304.71M (+21.3%)
|
200.71M
est: 154.39M (+30.0%)
|
539.40M
est: 539.69M (-0.1%)
|
367.25M
est: 385.19M (-4.7%)
|
429.43M
est: 502.91M (-14.6%)
|
530.19M
530.19M – 530.19M
+5.4% YoY
|
| SGA |
45.14M
est: 61.82M (-27.0%)
|
40.07M
est: 88.44M (-54.7%)
|
47.91M
est: 103.65M (-53.8%)
|
47.18M
est: 52.72M (-10.5%)
|
—
est: 57.32M (-100.0%)
|
67.07M
67.07M – 67.07M
+17.0% YoY
|
| EPS |
4.96
est: 3.77 (+31.4%)
|
2.68
est: 1.91 (+40.1%)
|
6.58
est: 6.69 (-1.6%)
|
4.14
est: 4.38 (-5.4%)
|
4.88
est: 5.72 (-14.6%)
|
6.03
6.03 – 6.03
+5.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-05 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-04 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.04% | 42.1K | 0.42% |
| 2 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.01% | 46.3K | 0.56% |
| 3 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 19.8K | 0.44% |
| 4 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 237.2K | 0.39% |
| 5 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 203.6K | 0.29% |
| 6 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 149.7K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Po-Ching Lee | Financial Manager | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6712.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
